MA41941A - Procédé de purification de protéines - Google Patents

Procédé de purification de protéines

Info

Publication number
MA41941A
MA41941A MA041941A MA41941A MA41941A MA 41941 A MA41941 A MA 41941A MA 041941 A MA041941 A MA 041941A MA 41941 A MA41941 A MA 41941A MA 41941 A MA41941 A MA 41941A
Authority
MA
Morocco
Prior art keywords
purification process
protein purification
protein
purification
Prior art date
Application number
MA041941A
Other languages
English (en)
Inventor
Sam Philip Heywood
Gavin Barry Wild
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA41941A publication Critical patent/MA41941A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041941A 2015-04-22 2016-04-20 Procédé de purification de protéines MA41941A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification

Publications (1)

Publication Number Publication Date
MA41941A true MA41941A (fr) 2018-02-28

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041941A MA41941A (fr) 2015-04-22 2016-04-20 Procédé de purification de protéines

Country Status (19)

Country Link
US (2) US10927164B2 (fr)
EP (1) EP3286205A1 (fr)
JP (2) JP6866300B2 (fr)
KR (1) KR102675400B1 (fr)
CN (1) CN107636012B (fr)
AR (1) AR104358A1 (fr)
AU (1) AU2016251223B2 (fr)
BR (1) BR112017022073A2 (fr)
CA (1) CA2983057C (fr)
CL (1) CL2017002614A1 (fr)
CO (1) CO2017010631A2 (fr)
EA (1) EA201792328A1 (fr)
GB (1) GB201506868D0 (fr)
IL (1) IL254883B (fr)
MA (1) MA41941A (fr)
MX (1) MX392543B (fr)
MY (1) MY189854A (fr)
SG (1) SG11201708256YA (fr)
WO (1) WO2016169992A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081540A1 (fr) * 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Matrice de chromatographie par affinité
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
SG11202112846RA (en) 2019-08-02 2021-12-30 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
EP4141025A4 (fr) * 2019-12-26 2024-04-24 ABL Bio, Inc. Procédé de purification d'un peptide biologiquement actif au moyen d'une chromatographie d'affinité à la protéine a
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
WO2025248017A1 (fr) * 2024-05-31 2025-12-04 UCB Biopharma SRL Procédé de purification de protéines de recombinaison

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
WO2000069457A1 (fr) 1999-05-15 2000-11-23 University Of California, San Diego Domaines avec activites voulues fondes sur la proteine a
EP1353937A4 (fr) * 2000-12-29 2005-04-13 Savient Pharmaceuticals Inc Anticorps humains specifiques pour la therapie selective du cancer
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインaアフィニティークロマトグラフィーを用いる抗体の精製方法
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
EA201300524A1 (ru) * 2010-11-01 2013-08-30 ДСМ АйПи АССЕТС Б.В. Очистка антител ионообменной хроматографией в едином блоке
US8859726B2 (en) 2010-11-29 2014-10-14 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
MX2014009565A (es) * 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AP2016009222A0 (en) * 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
US20210171609A1 (en) 2021-06-10
AU2016251223B2 (en) 2021-12-09
IL254883B (en) 2021-09-30
KR20170139131A (ko) 2017-12-18
CO2017010631A2 (es) 2018-01-05
JP6866300B2 (ja) 2021-04-28
CL2017002614A1 (es) 2018-04-27
GB201506868D0 (en) 2015-06-03
CN107636012A (zh) 2018-01-26
WO2016169992A1 (fr) 2016-10-27
JP2018520089A (ja) 2018-07-26
US10927164B2 (en) 2021-02-23
AR104358A1 (es) 2017-07-12
JP2021066734A (ja) 2021-04-30
US20180100007A1 (en) 2018-04-12
KR102675400B1 (ko) 2024-06-13
EP3286205A1 (fr) 2018-02-28
CA2983057A1 (fr) 2016-10-27
IL254883A0 (en) 2017-12-31
AU2016251223A1 (en) 2017-10-26
BR112017022073A2 (pt) 2018-08-14
MX2017013333A (es) 2018-02-19
CN107636012B (zh) 2022-08-02
CA2983057C (fr) 2025-05-06
MY189854A (en) 2022-03-14
SG11201708256YA (en) 2017-11-29
US12516106B2 (en) 2026-01-06
MX392543B (es) 2025-03-19
EA201792328A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
EP3564866A4 (fr) Procédé de calcul
EP3392266A4 (fr) Procédé de synthèse de linaclotide
EP3342546A4 (fr) Système de robot
EP3004135A4 (fr) Procédé de purification de protéine
DK3341479T3 (da) LNA-G-Proces
EP3412623A4 (fr) Procédé de purification
DK3416974T3 (da) Proteinoprensning
MA43944A (fr) Procédé de purification de liquide
HUE057118T2 (hu) Folyamat
IL254883B (en) A method for protein purification
EP3380628A4 (fr) Procédé de broyage
EP3521299A4 (fr) Procédé de purification de protéine recombinée
EP2975020A4 (fr) Procédé de purification de 1,5-diaminopentane
EP3505263A4 (fr) Procédé de purification de sol souterrain
EP3265120C0 (fr) Procédé
PT3256546T (pt) Processo de despolimerização
EP3318552A4 (fr) Procédé de purification de méthionine
EP3626804A4 (fr) Procédé de purification de raffinat-2
EP2970857A4 (fr) Nouveau procédé de purification protéique
EP3333571A4 (fr) Procédé de quantification parallèle de variant de protéine
MA46454A (fr) Procédé multi-protéase
EP3481839C0 (fr) Procédé de purification de méthylcobalamine
MA42658A (fr) Procédé de réduction de pathogènes
EP3404037A4 (fr) Procédé de purification de fibrinogène
SG11201802755WA (en) Process for purification of methyl methacrylate